Riskpilot← Back to searchSign inGet full accessBellman & Symfon Group AB
ABActiveOrg 5567126023Södra Långebergsgatan 30Wholesale of pharmaceutical and medical goods · NACE 4646Est. 200610-19 employees
Revenue 2024
SEK 92,7M
+1% vs 2023
EBITDA margin
-1.5%
+23% vs 2023
Equity ratio
52.2%
Financial strength
Net profit 2024
SEK 12,4M
+148% vs 2023
| Revenue | SEK 92,7M | +1% |
| EBITDA | SEK -1,4M | +23% |
| Net profit | SEK 12,4M | +148% |
| Total assets | SEK 77,9M | +16% |
| Equity | SEK 40,7M | +75% |
| Employees | — | — |
Legal name
Bellman & Symfon Group AB
Org number
5567126023
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
10 oktober 2006
Share capital
SEK 100 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Jungvid, Peter Gustaf
Company purpose
Bolaget ska bedriva industriell verksamhet inom det medicin- tekniska och signalelektriska området. Bolaget ska även utveckla och förvalta immateriella rättigheter såsom patent, mönsterskydd och varumärken, hantera finansiella tillgångar, ansvara för centrala funktioner inom koncernen samt bedriva därmed förenlig verksamhet.
Address
Södra Långebergsgatan 30
Email
pj@bellman.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 62 075 | 84 027 | 84 076 | 91 783 | 92 709 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 2 302 | −3 267 | −3 338 | −1 846 | −1 429 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | 2 302 | −3 267 | −3 338 | −1 846 | −1 429 |
| Net financials | −239 | −344 | 196 | −1 799 | −2 106 |
| Profit before tax | 1 523 | 8 613 | 12 858 | 6 854 | 15 393 |
| Tax | −347 | −1 785 | −2 688 | −1 847 | −2 998 |
| Net profit | 1 176 | 6 828 | 10 170 | 5 007 | 12 395 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 46 415 | 64 075 | 54 559 | 66 953 | 77 906 |
| Equity | 1 280 | 8 109 | 18 279 | 23 287 | 40 655 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 44 595 | 52 071 | 32 851 | 36 437 | 35 403 |
| Total debt | 44 595 | 52 071 | 32 851 | 36 437 | 35 403 |
EBITDA margin
-1.5%
This company
15.8%
Market median
-109% vs market
20202024
Equity ratio
52.2%
This company
38.2%
Market median
+37% vs market
20202024
Return on equity
30.5%
This company
18.4%
Market median
+66% vs market
20202024
Net profit margin
13.4%
This company
8.1%
Market median
+65% vs market
20202024
Asset turnover
1.19×
This company
1.12×
Market median
+6% vs market
20202024
Debt / equity
0.92×
This company
0.62×
Market median
+48% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
PG Chief Executive Officer | Chief Executive Officer | 2025 |
SH Audit | Audit | 2020 |
| Former (1) | ||
KD Chief Executive Officer | Chief Executive Officer | 2025 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
| Former (7) | ||
| Deputy Board Member | 2022 – 2023 | |
| Chairman | 2021 – 2022 | |
| Board of Directors | 2020 – 2024 | |
| Board of Directors | 2020 – 2021 | |
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2022 – 2024 | |
| Chairman | 2022 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Lifeon AB
Bellman & Symfon Group AB (this company)Bellman & Symfon North America IncBellman & Symfon Asia LtdBELLMAN & SYMFON NORTH AMERICA INCBellman & Symfon Nederland BvBellman & Symfon Uk LtdBellman & Symfon Norge ASBellman & Symfon Deutschland GmbhBellman & Symfon Netherlands BvAurismed ASBELLMAN & SYMFON DEUTSCHLAND GMBHBELLMAN & SYMFON NORGE ASBELLMAN & SYMFON NEDERLAND BVBELLMAN & SYMFON UK LTDBELLMAN & SYMFON NETHERLANDS BVBELLMAN & SYMFON ASIA LTDBoard members of Bellman & Symfon Group AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Gustaf Jungvid | Chief Executive Officer | 0 companies |
| Karl David Rosén | Chief Executive Officer | 0 companies |
| Stefan Hugo Kylebäck | Audit | 0 companies |
| Jan Eric Bergström | Board of Directors | 0 companies |
| Evert Dijkstra | Board of Directors | 0 companies |
| Anders Carl-Johan Ingemarsson | Deputy Board Member | 0 companies |
| Anders Peter Fogelberg | Chairman | 0 companies |
| Xiao Xuan Xie | Board of Directors | 0 companies |
| Peter Anders Torstensson | Board of Directors | 0 companies |
| Henrik Håkan Mattias Holm | Deputy Board Member | 0 companies |
| Elin Rebecka Öhman | Deputy Board Member | 0 companies |
| Lars Fredrik Petersson | Chairman | 0 companies |